The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
PEGylation in anti-cancer therapy: An overview
Open accessAbstract
Advanced drug delivery systems using poly(ethylene glycol) (PEG) is an important development in anti-cancer therapy. PEGylation has the ability to enhance the retention time of the therapeutics like proteins, enzymes small molecular drugs, liposomes and nanoparticles by protecting them against various degrading mechanisms active inside a tissue or cell, which consequently improves their therapeutic potential. PEGylation effectively alters the pharmacokinetics (PK) of a variety of drugs and dramatically improves the pharmaceutical values; recent development of which includes fabrication of stimuli-sensitive polymers/smart polymers and polymeric micelles to cope of with the pathophysiological environment of targeted site with less toxic effects and more effectiveness. This overview discusses PEGylation involving proteins, enzymes, low molecular weight drugs, liposomes and nanoparticles that has been developed, clinically tried for anti-cancer therapy during the last decade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jain, P. K., Huang, X., El-Sayed, I. H., & El-Sayed, M. A. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002804 · Cited by 4,215
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 1×
“In this regard, polyethylene glycol (PEG), a water-soluble and biocompatible polymer, is the most commonly used non-ionic polymer in the field of polymer-based drug delivery [1].”
BackgroundNanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910 · cited 1×
“Self-assembling amphiphilic polymeric micelles represents an efficient drug delivery system for soluble or insoluble drugs [84].”
BackgroundStructure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Chemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Allen, T. M., Hansen, C., Martin, F., Redemann, C., & Yau-Young, A. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90246-5 · Cited by 1,391
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Polymeric micelles—A new generation of colloidal drug carriers
Jones, M.-C., & Leroux, J.-C. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00039-9 · Cited by 1,256
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
Caliceti, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00108-x · Cited by 947
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Yamaoka, T., Tabata, Y., & Ikada, Y. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830432 · Cited by 748
Mishra, S., Webster, P., & Davis, M. E. (2004) · European Journal of Cell Biology · doi:10.1078/0171-9335-00363 · Cited by 730
Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645
Folate receptor targeted biodegradable polymeric doxorubicin micelles
Yoo, H. S., & Park, T. G. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.003 · Cited by 620
Green, M. D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., Siena, S., Lalisang, R. I., Samonigg, H., Clemens, M. R., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg019 · Cited by 586
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Delivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Kwon, G. S. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i5.20 · Cited by 502 · cited 1×
“The water-soluble PEG blocks with a molecular weight from 1 to 15 kDa are considered as the most suitable hydrophilic corona-forming blocks [87].”
BackgroundPreclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Matsumura, Y., & Kataoka, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01103.x · Cited by 501
Hatakeyama, H., Akita, H., & Harashima, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00059 · Cited by 495
Vogel, C. L., Wojtukiewicz, M. Z., Carroll, R. R., Tjulandin, S. A., Barajas-Figueroa, L. J., Wiens, B. L., Neumann, T. A., & Schwartzberg, L. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.102 · Cited by 482
Cancer theranostics: the rise of targeted magnetic nanoparticles
Cole, A. J., Yang, V. C., & David, A. E. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2011.03.001 · Cited by 425
The uses and properties of PEG-linked proteins.
Delgado, C., Francis, G. E., & Fisher, D. (1992) · PubMed · Cited by 420
Wang, Y.-S., Youngster, S., Grace, M., Bausch, J., Bordens, R., & Wyss, D. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00027-3 · Cited by 420
Hatakeyama, H., Akita, H., Kogure, K., Oishi, M., Nagasaki, Y., Kihira, Y., Ueno, M., Kobayashi, H., Kikuchi, H., & Harashima, H. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302843 · Cited by 398
Plummer, R., Wilson, R. H., Calvert, H., Boddy, A. V., Griffin, M., Sludden, J., Tilby, M. J., Eatock, M., Pearson, D. G., Ottley, C. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.6 · Cited by 390
Allen, C., Dos Santos, N., Gallagher, R., Chiu, G. N. C., Shu, Y., Li, W. M., Johnstone, S. A., Janoff, A. S., Mayer, L. D., Webb, M. S., et al. (2002) · Bioscience Reports · doi:10.1023/a:1020186505848 · Cited by 388
Bhat, R., & Timasheff, S. N. (1992) · Protein Science · doi:10.1002/pro.5560010907 · Cited by 374
Seymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., & Duncan, R. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00514-6 · Cited by 337
Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-991 · Cited by 324
Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., & Harashima, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.009 · Cited by 309
Mono-N-terminal poly(ethylene glycol)–protein conjugates
Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., & Gegg, C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00023-6 · Cited by 306
Holmes, F. A., Jones, S. E., O’Shaughnessy, J., Vukelja, S., George, T., Savin, M., Richards, D., Glaspy, J., Meza, L., Cohen, G., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf130 · Cited by 291
The enzyme as drug: application of enzymes as pharmaceuticals
Vellard, M. (2003) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(03)00092-2 · Cited by 283
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Banerjee, S. S., Aher, N., Patil, R., & Khandare, J. (2012) · Journal of Drug Delivery · doi:10.1155/2012/103973 · Cited by 282
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 279
Cheng, P. N.-M., Lam, T.-L., Lam, W.-M., Tsui, S.-M., Cheng, A. W.-M., Lo, W.-H., & Leung, Y.-C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1945 · Cited by 277
The therapeutic value of poly(ethylene glycol)-modified proteins
Nucci, M. L., Shorr, R., & Abuchowski, A. (1991) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(91)90037-d · Cited by 276
Newman, M. S., Colbern, G. T., Working, P. K., Engbers, C., & Amantea, M. A. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050855 · Cited by 275
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies
Matsumura, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.010 · Cited by 275
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
Rahman, A. M., Yusuf, S. W., & Ewer, M. S. (2007) · PubMed Central · Cited by 267
A Branched Monomethoxypoly(ethylene glycol) for Protein Modification
Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J. M., & Veronese, F. M. (1995) · Bioconjugate Chemistry · doi:10.1021/bc00031a006 · Cited by 257
Liposomal drug formulations in cancer therapy: 15 years along the road
Slingerland, M., Guchelaar, H.-J., & Gelderblom, H. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.015 · Cited by 250
Polyethylene glycol-conjugated pharmaceutical proteins
Bailon, P., & Berthold, W. (1998) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(98)00086-8 · Cited by 243
Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C
Rajender Reddy, K., Modi, M. W., & Pedder, S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00028-5 · Cited by 241
Ascierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0933 · Cited by 238
Nanotechnology for Cancer Therapy
(2006) · CRC Press eBooks · doi:10.1201/9781420006636 · Cited by 235
Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia.
Meyer, D. E., Kong, G., Dewhirst, M. W., Zalutsky, M. R., & Chilkoti, A. (2001) · PubMed · Cited by 226
Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA–PEG–folate conjugate
Esmaeili, F., Ghahremani, M. H., Ostad, S. N., Atyabi, F., Seyedabadi, M., Malekshahi, M. R., Amini, M., & Dinarvand, R. (2008) · Journal of Drug Targeting · doi:10.1080/10611860802088630 · Cited by 203
Cruz, L. J., Tacken, P. J., Fokkink, R., & Figdor, C. G. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.082 · Cited by 201
Zhang, F., Zhang, S., Pollack, S. F., Li, R., Gonzalez, A. M., Fan, J., Zou, J., Leininger, S. E., Pavía-Sanders, A., Johnson, R., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512616s · Cited by 191
Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy
Lee, J.-M., Yoon, T.-J., & Cho, Y.-S. (2013) · BioMed Research International · doi:10.1155/2013/782041 · Cited by 190
Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers
Zhao, H., Rubio, B., Sapra, P., Wu, D., Reddy, P., Sai, P., Martinez, A., Gao, Y., Lozanguiez, Y., Longley, C., et al. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700333s · Cited by 188
Glazer, E. S., Piccirillo, M., Albino, V., Di Giacomo, R., Palaia, R., Mastro, A. A., Beneduce, G., Castello, G., De Rosa, V., Petrillo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7765 · Cited by 187
Pillai, G. (2014) · SOJ Pharmacy & Pharmaceutical Sciences · doi:10.15226/2374-6866/1/2/00109 · Cited by 187
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
Lao, J., Madani, J., Puértolas, T., Álvarez, M., Hernández, A., Pazo-Cid, R., Artal, Á., & Antón Torres, A. (2013) · Journal of Drug Delivery · doi:10.1155/2013/456409 · Cited by 185
Sapra, P., Zhao, H., Mehlig, M., Malaby, J., Kraft, P., Longley, C., Greenberger, L. M., & Horak, I. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4456 · Cited by 168
Holtsberg, F. W., Ensor, M., Steiner, M. R., Bomalaski, J. S., & Clark, M. A. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00042-1 · Cited by 155
Yarmolenko, P., Zhao, Y., Landon, C. D., Spasojević, I., Yuan, F., Needham, D., Viglianti, B. L., & Dewhirst, M. W. (2010) · International Journal of Hyperthermia · doi:10.3109/02656731003789284 · Cited by 154
Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers
Miteva, M., Kirkbride, K. C., Kilchrist, K. V., Werfel, T. A., Li, H., Nelson, C. E., Gupta, M. K., Giorgio, T. D., & Duvall, C. L. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.036 · Cited by 151
Use of liposomal anthracyclines in Kaposi’s sarcoma
Krown, S. E., Northfelt, D., Osoba, D., & Stewart, J. S. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.003 · Cited by 150
Remaut, K., Lucas, B., Braeckmans, K., Demeester, J., & Smedt, S. C. D. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.029 · Cited by 146
Pillai, G. (2014) · SOJ Pharmacy & Pharmaceutical Sciences · doi:10.15226/2374-6866/1/1/00109 · Cited by 135
Suzuki, T., Ichihara, M., Hyodo, K., Yamamoto, E., Ishida, T., Kiwada, H., Ishihara, H., & Kikuchi, H. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.049 · Cited by 127
The targeted behavior of thermally responsive nanohydrogel evaluated by NIR system in mouse model
Zhang, J., Chen, H., Xu, L. S., & Gu, Y. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.019 · Cited by 102
Herndon, T. M., Demko, S., Jiang, X., He, K., Gootenberg, J. E., Cohen, M. H., Keegan, P., & Pazdur, R. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0123 · Cited by 86
The Drug Discovery by NanoMedicine and its Clinical Experience
Matsumura, Y. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu046 · Cited by 82
Awada, A. H., García, A. A., Chan, S. Y. T., Jérusalem, G., Coleman, R. E., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70429-7 · Cited by 80
Ton, N. C., Parker, G. J. M., Jackson, A., Mullamitha, S., Buonaccorsi, G. A., Roberts, C., Watson, Y., Davies, K. E., Cheung, S., Hope, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1550 · Cited by 78
Deng, Y., Yang, P., Ma, Zhao, She, Wang, Li, X., & Wang (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s41701 · Cited by 65
Cheng, P., Leung, Y., Lo, W., Tsui, S. M., & Lam, K. C. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.050 · Cited by 64
Hoch, U., Staschen, C., Johnson, R. K., & Eldon, M. A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2577-7 · Cited by 55
Jameson, G., Hamm, J. T., Weiss, G. J., Alemany, C. A., Anthony, S. P., Basche, M., Ramanathan, R. K., Borad, M. J., Tibes, R., Cohn, A. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1201 · Cited by 55
PEGylation: Posttranslational bioengineering of protein biotherapeutics
Veronese, F. M., & Pasut, G. (2008) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2009.02.002 · Cited by 54
Chen, B.-A., Bao, W., Liu, R., Wang, Y., Wang, F., Xia, G., Zhang, H., Li, X., & Yin, H. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s75090 · Cited by 49
Vergote, I. B., García, A. A., Micha, J. P., Pippitt, C. H., Bendell, J. C., Spitz, D. L., Reed, N. S., Dark, G. G., Fracasso, P. M., Ibrahim, E. N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1278 · Cited by 47
Carbohydrate PEGylation, an approach to improve pharmacological potency
Giorgi, M. E., Agusti, R., & de Lederkremer, R. M. (2014) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.10.147 · Cited by 44
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
“Few candidates, however, have progressed from the benchtop to the market [23,24], with factors such as a limited in vivo stability and undesirable off-target effects likely contributing to a lack of translational success [10].”
Background
Metadata
- Authors
- Mishra, P., Nayak, B., & Dey, R. K.
- Venue
- Asian Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 11
- Issue
- 3
- Pages
- 337-348
- ISSN
- 1818-0876 (ISSN-L)
- OpenAlex
- W1630018437
- Cited by
- 382
- References
- 88
- FWCI
- 8.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.